Clinical Trial

Evaluate the Efficacy and Safety of Xianglei Tangzu Gao for the Treatment of Wagner Grade II Diabetic Foot Ulcers

Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
This is a phase II/III seamless design, randomized, double-blind, paralleled-group, placebo-controlled study to evaluate the efficacy and safety of Xianglei Tangzu Gao for the treatment of Wagner grade II diabetic foot ulcers. The primary endpoint is the proportion of subjects with complete closure of target ulcer during the 16-week treatment phase.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-07-29; most recent amendment 2026-06-10.
Status change: Recruiting → Active, Not Recruiting 2026-06-10
Status change: Not Yet Recruiting → Recruiting 2024-08-15
Trial Details
NCT Number NCT06531512
Lead Sponsor Oneness Biotech Co., Ltd.
Conditions Diabetic Foot Ulcer
Enrollment 120 participants
Start Date 2024-08-16
Primary Completion 2026-05-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-12